Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder

Depression and Anxiety

Volumn 25, Issue 10, 2008, Pages 854-861

  Bose, Anjana ^a,b   Korotzer, Andrew ^a   Gommoll, Carl ^a   Li, Dayong ^a  

^a Harborside Financial Center   (United States)

^b FOREST RESEARCH INSTITUTE   (United States)

Author keywords

Efficacy; GAD; Safety; SNRI; SSRI; Tolerability

Indexed keywords

ESCITALOPRAM; PLACEBO; VENLAFAXINE;

ADULT; AGED; ARTICLE; BASAL CELL CARCINOMA; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EJACULATION DISORDER; FATIGUE; FEMALE; GENERALIZED ANXIETY DISORDER; HAMILTON ANXIETY SCALE; HEADACHE; HUMAN; IMPOTENCE; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOMNOLENCE; SWEATING; XEROSTOMIA;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANXIETY DISORDERS; CITALOPRAM; CYCLOHEXANOLS; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PERSONALITY ASSESSMENT; PERSONALITY INVENTORY; PSYCHOMETRICS; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 55549138381     PISSN: 10914269     EISSN: 15206394     Source Type: Journal    
DOI: 10.1002/da.20355     Document Type: Article

References (35)

1. Allgulander C, Hackett D, Salinas E. 2001. Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study. Br J Psychiatry 179:15-22.
2. Allgulander C, Florea I, Huusom AK. 2005. Prevention of relapse in generalized anxiety disorder by escitalopram treatment. Int J Neuropsychopharmacol 9:1-11.
3. Anderson IM. 2000. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 58:19-36.
4. APA. 2000. Diagnostic and Statistical Manual of Mental Disorders IV TR. Washington, DC: American Psychiatric Association.
5. Baldwin DS, Huusom AK, Maehlum E. 2006. Escitalopram and paroxetine in the treatment of generalised anxiety disorder: randomised, placebo-controlled, double-blind study. Br J Psychiatry 189:264-272.
6. Baldwin DS, Nair RV. 2005. Escitalopram in the treatment of generalized anxiety disorder. Expert Rev Neurother 5:443-449.
7. Baldwin DS, Polkinghorn C. 2005. Evidence-based pharmacotherapy of Generalized Anxiety Disorder. Int J Neuropsychopharmacol 8:293-302.
8. Bielski RJ, Ventura D, Chang CC. 2004. A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. J Clin Psychiatry 65:1190-1196.
9. Davidson JR, DuPont RL, Hedges D, Haskins JT. 1999. Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. J Clin Psychiatry 60:528-535.
10. Degner D, Grohmann R, Kropp S, Ruther E, Bender S, Engel RR, Schmidt LG. 2004. Severe adverse drug reactions of antidepressants: results of the German multicenter drug surveillance program AMSP. Pharmacopsychiatry 37(Suppl 1):S39-S45.
11. Endicott J, Nee J, Harrison W, Blumenthal R. 1993. Quality of life enjoyment and satisfaction questionnaire: a new measure. Psychopharmacol Bull 29:321-326.
12. Feighner JP. 1995. Cardiovascular safety in depressed patients: focus on venlafaxine. J Clin Psychiatry 56:574-579.
13. Gelenberg AJ, Lydiard RB, Rudolph RL, Aguiar L, Haskins JT, Salinas E. 2000. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: a 6-month randomized controlled trial. JAMA 283:3082-3088.
14. Goodman WK, Bose A, Wang Q. 2005. Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials. J Affect Disord 87:161-167.
15. Greenberg PE, Sisitsky T, Kessler RC, Finkelstein SN, Berndt ER, Davidson JR, Ballenger JC, Fyer AJ. 1999. The economic burden of anxiety disorders in the 1990s. J Clin Psychiatry 60:427-435.
16. Guy W. 1976. ECDEU Assessment Manual for Psychopharmacology. Washington, DC: Superintendent of Documents, US Government Printing Office, US Department of Health, Education, and Welfare Publication No. 76-338.
17. Hamilton M. 1959. The assessment of anxiety states by rating. Br J Med Psychol 32:50-55.
18. Hamilton M. 1960. A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62.
19. Harvey AT, Rudolph RL, Preskorn SH. 2000. Evidence of the dual mechanisms of action of venlafaxine. Arch Gen Psychiatry 57:503-509.
20. Hoehn-Saric R, McLeod DR, Zimmerli WD. 1988. Differential effects of alprazolam and imipramine in generalized anxiety disorder: somatic versus psychic symptoms. J Clin Psychiatry 49:293-301.
21. Huskisson EC. 1974. Measurement of pain. Lancet 2:1127-1131.
22. Kessler RC, DuPont RL, Berglund P, Wittchen HU. 1999. Impairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national surveys. Am J Psychiatry 156:1915-1923.
23. Montgomery SA, Huusom AK, Bothmer J. 2004. A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobiology 50:57-64.
24. Nemeroff CB, Entsuah R, Benattia I, Demitrack M, Sloan DM, Thase ME. 2007. Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs [published online ahead of print September 20, 2007] Biol Psychiatry doi: 10.1016/j.biopsych.2007.06.027.
25. Noyes R Jr. 2001. Comorbidity in generalized anxiety disorder. Psychiatr Clin N Am 24:41-55.
26. Owens MJ, Knight DL, Nemeroff CB. 2001. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry 50:345-350.
27. Rickels K, Pollack MH, Sheehan DV, Haskins JT. 2000. Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. Am J Psychiatry 157:968-974.
28. Sheehan DV. 1983. The anxiety disease. New York: Scribner and Sons.
29. Stahl SM. 2002. Don't ask, don't tell, but benzodiazepines are still the leading treatments for anxiety disorder. J Clin Psychiatry 63:756-757.
30. Thase ME. 1998. Effects of venlafaxine on blood pressure: a metaanalysis of original data from 3744 depressed patients. J Clin Psychiatry 59:502-508.
31. Thase ME, Entsuah AR, Rudolph RL. 2001. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 178:234-241.
32. Wittchen HU. 2002. Generalized anxiety disorder: prevalence, burden, and cost to society. Depress Anxiety 16:162-171.
33. Wittchen HU, Zhao S, Kessler RC, Eaton WW. 1994. DSM-III-R generalized anxiety disorder in the National Comorbidity Survey. Arch Gen Psychiatry 51:355-364.
34. Yonkers KA, Dyck IR, Warshaw M, Keller MB. 2000. Factors predicting the clinical course of generalised anxiety disorder. Br J Psychiatry 176:544-549.
35. Zigmond AS, Snaith RP. 1983. The hospital anxiety and depression scale. Acta Psychiatr Scand 67:361-370.